Top Pharmaceuticals & Healthcare Distributors 2026

Part of Top Distributors 2026 — the Anglera Index: North America’s largest distributors ranked, classified into six operating archetypes, and scored on the measured Digital Readiness Index.

The three largest companies in this vertical are also the three largest companies in the entire Top Distributors 2026 index, and none of them carries a Digital Readiness score. That is the finding this cut turns on: McKesson, Cencora, and Cardinal Health move a combined $900 billion or so of pharmaceuticals a year through account-gated ordering systems, and the only Digital Readiness Index score recorded anywhere in Pharmaceuticals & Healthcare belongs to a company that ranks seventh in the vertical by revenue.

The ranking

Revenue figures are each company's total, most recently reported fiscal-year revenue as given in the source data, not a pharma-only or healthcare-only segment figure. Owens & Minor is the exception: its $8.0B is the FY2024 distribution-segment figure, the last full year before that segment changed hands mid-cut; see below.

Why scale-aggregators own this vertical

Every company at the top of this list carries a scale-aggregator archetype, and the archetype rationale behind each is nearly identical in shape even though the numbers differ by hundreds of billions of dollars. McKesson delivers roughly a third of all pharmaceutical products consumed in North America through a centralized national network. Cencora moves roughly 20% of all US pharmaceuticals through a footprint of only about 26 US distribution centers plus nine in Canada. Cardinal Health serves more than 100,000 locations and over 75% of US hospitals, and runs Red Oak Sourcing, its generic-drug joint purchasing venture with CVS, described in the data as the largest generic sourcing operation in the country. None of that is order-taking off a web catalog. It is national-network density and negotiated buying power applied to a product category, pharmaceuticals, where price is set per contract and controlled substances move through DEA-tracked account channels rather than an anonymous storefront.

That structural fact explains the DRI table better than any catalog quality judgment could, though an August verification pass complicated it in an interesting way. The data now records only McKesson as no-public-catalog: its corporate site is brochureware, and even its medical-surgical storefront, mms.mckesson.com, surfaces only category landing pages such as /content/anesthesia/ rather than product detail pages a crawler could parse. Cencora and Cardinal Health both moved to catalog found, not yet sampled. Cencora's corporate site is still a B2B lead-generation platform with no shop or store section reachable, but its specialty business ASD Healthcare publishes a public catalog with real product pages — name, NDC, manufacturer, storage details, no login required. Cardinal Health's core distribution ordering still runs through login-gated portals like Order Express, yet its Canadian storefront and its Edgepark home-delivery site both render full product pages anonymously. Neither carries a score this edition, because scores are only published from rule-compliant samples. And the finding is still not a zero. It states that these companies chose an account-based commercial model for pharmaceutical distribution, a defensible and arguably necessary choice given what they sell — the public pages live at the edges of the business, not at its pharmaceutical core.

The exception, and the second archetype in this vertical, is program-supplier: companies that pair a catalog with an embedded relationship. Medline manufactures its own private-label products, including wound-care lines sold under CVS, Walgreens, Target, and Dollar General brands, and deploys roughly 2,000 direct sales reps into hospitals. Henry Schein bundles its Henry Schein One practice-management software with consumables sold into dental and medical practices, pushing the relationship past a transactional order. Owens & Minor ran the same play at hospital scale with MediChoice private label and VMI supply-chain services, until its medical-surgical distribution segment, Products & Healthcare Services, was sold to Platinum Equity for $375 million in a deal that closed December 31, 2025. The remaining public company rebranded as Accendra Health, Inc. (NYSE: ACH) on January 2, 2026, keeping only the home-based care business, Apria and Byram. That move split a scale-aggregator archetype away from a company's public identity within a single fiscal year, as clean a demonstration as this index has of how fast archetype and ownership can diverge from the name on the door.

What the Digital Readiness Index actually found

Only one company in Pharmaceuticals & Healthcare cleared measurement: Thermo Fisher Scientific, at 59 out of 100, exactly the vertical's median because it is the vertical's only data point. That score sits almost precisely at the index-wide median of 58, which is itself worth noting: the one healthcare-adjacent company with a real digital shelf performs like an average distributor across the whole index, not like a laggard and not like a standout.

The pillar breakdown is where the interesting detail lives. Thermo Fisher's product data depth pillar scored 17.9 of 35, the weakest of the four, and its GTIN rate on sampled pages was 0%, meaning none of the five sampled pages carried a standard product identifier a machine could use to match the item to the same SKU elsewhere. For a catalog spanning Thermo Scientific, Invitrogen, Applied Biosystems, Gibco, and Fisher Scientific branded lines, that is a real gap: a lab buyer or procurement system trying to cross-reference a reagent or consumable across suppliers has nothing but the manufacturer's own part number to work from. The median attribute count on a sampled page was 13, which is enough to describe a general product but thin for the kind of filtering a clinical or lab buyer actually needs, things like reagent grade, storage temperature, container volume, sterility, and compatibility with specific instrument platforms. The consistency spread of 22 points between the richest and thinnest sampled page says that depth is uneven across categories, which matters more than the median for a buyer who happens to land on a thin page.

Where Thermo Fisher did well: agent readiness scored a full 20 of 20, with product structured data present, a working sitemap, and no explicit AI crawler block, which under this index's scoring rules means full marks on that signal rather than a gap. Public pricing appeared on 60% of sampled pages, a partial but real improvement over the account-gated norm elsewhere in the vertical. Commerce transparency landed at 12 of 20, ahead of where a fully gated wholesaler would fall by definition, since there is no wholesaler comparison point in this vertical to set the bar.

Medline is the case worth watching rather than scoring. Its driNote records that individual product detail pages are publicly viewable, full name, images, features and benefits, a spec table, and SKU list, with no login required, and only final purchase pricing gated behind a sign-in wall. But an August re-test in a full Chrome browser session got a completely blank page, so the honest status is "not observable": a limit of the measurement, not a claim about the data behind the wall — and distinct from having no catalog at all.

Where this is heading

McKesson's announced spin-off of its Medical-Surgical unit into an independent public company and Owens & Minor's split into Accendra Health both point the same direction: the pharmaceutical wholesale core, the part that will never run a public storefront because of contract pricing and controlled-substance handling, is being separated from the medical-surgical and home-care businesses that could plausibly build one. If that separation continues across the vertical, the next edition of this index may have more companies to measure, not because the giants changed their model, but because their catalog-adjacent businesses stopped being folded inside them.